Can cutting unnecessary pills improve kidney patient health?

NCT ID NCT06324045

Recruiting now Disease control Sponsor: Hamad Medical Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial tests whether a team of doctors and pharmacists can safely reduce the number of unnecessary medications taken by people with chronic kidney disease in Qatar. 424 patients will be randomly assigned to receive the deprescribing program or usual care. The goal is to see if this approach lowers the use of risky medications and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: deprescribing program (medication review and reduction plan)
What this could lead to: If successful, this could show that a structured deprescribing program safely reduces medication burden and improves quality of life for people with chronic kidney disease.
What could go wrong: This is a relatively small, single-country trial testing a behavioral intervention, not a drug. Results may not apply to other settings, and deprescribing carries risks if medications are stopped inappropriately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Hamad Medical Corporation
RECRUITING

Doha, 3050, Qatar

More trials for these conditions

Other studies related to the condition(s) this trial covers.